The study will enrol patients aged 18–65 years, diagnosed with gMG (Myasthenia Gravis Foundation of America disease class III–IVa) who are either acetylcholine receptor positive (AChR+), or muscle‐specific kinase positive (MuSK+), with a Myasthenia Gravis Activities of Daily Living (MG‐ADL) score ≥6, and persistent MG symptoms despite adequate treatment courses with at least two different non‐steroidal immunosuppressive drugs. This evidence concerns the gene MUSK and Fatigable weakness.